UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A | N/A | N/A |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| OTC |
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry into a Material Definitive Agreement. |
On May 6, 2026, Odyssey Health, Inc., a Nevada corporation (the "Company" "Odyssey"), received formal written notice from NeuRX Health, Inc. ("NeuRX"), a Wyoming corporation, advising that NeuRX is in breach of its contractual obligations with Davion Healthcare Plc ("Davion"), an Irish corporation, in connection with Davion's BreastCheck product. Specifically, NeuRX failed to obtain Davion's required approval prior to sublicensing the BreastCheck product to Odyssey. In addition, NeuRX breached the Representations and Warranties contained in the definitive agreement, under which NeuRX had expressly warranted to Odyssey that all necessary consents and approvals had been obtained. As a result, the notice stated that the definitive agreement between Odyssey and NeuRX, dated October 14, 2025, and which closed on April 21, 2026, is immediately cancelled.
The information set forth in this Form 8-K Current Report filed on May 11, 2026, is hereby incorporated by reference into this Form 8-K Current Report.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description |
| 10.1 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Odyssey Health, Inc. | ||
| Date: May 11, 2026 | By: | /s/ Joseph Michael Redmond |
| Joseph Michael Redmond Chief Executive Officer | ||
| 3 |